Canada. The Canadian product monograph for epoetin alfa (Eprex) has been revised to include information regarding a possible increased incidence of thrombosis in patients with cancer who have high haemoglobin levels (>120 g/L). The 'Dear Health-are Professional' letter issued by Janssen-Ortho Inc, in consultation with Health Canada, advises that the Contraindications, Warnings, Precautions, Adverse Reactions, Dosage and Administration and Information for the Patient sections have been updated to reflect this safety information.

Reference:

'Dear Health-care Professional' letter from Janssen-Ortho Inc, 13 October 2004. Available on the Internet at www.hc-sc.gc.ca

Reports in WHO-file: Thrombosis 105